| Business Summary | | I-Flow
Corporation
designs,
develops,
manufactures
and
markets
technically
advanced,
low-cost
ambulatory
drug
delivery
systems
that
provide
life
enhancing,
cost
effective
solutions
for
pain
management
and
infusion
therapy.
The
Company's
products
are
used
both
in
hospitals
and
alternate
site
settings.
I-Flow
offers
the
health
care
professional
an
array
of
cost-effective
drug
delivery
devices
designed
to
meet
the
needs
of
today's
managed
care
environment,
both
in
the
hospital
and
alternate
site
setting.
The
I-Flow
family
of
products
is
focused
on
three
primary
market
segments:
Regional
Anesthesia,
IV
Infusion
Therapy
and
Oncology
Infusion
Services. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | I-Flow
Corporation
designs,
develops,
manufactures
and
markets
ambulatory
infusion
systems
that
administer
antibiotics,
analgesics,
chemotherapeutic
agents,
hormones,
nutrients,
hyrdation
therapies
and
other
medical
treatments
to
patients.
For
the
six
months
ended
6/30/01,
revenues
rose
8%
to
$16.5
million.
Net
income
rose
5%
to
$715
thousand.
Results
reflect
increased
Onocology
Infusion
Services
sales,
partially
offset
by
increased
costs
from
the
Infusystem
subsidiary. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Donald Earhart, 56 Chairman,
Pres, CEO | $751K | -- | James Talevich, 50 CFO,
Treasurer | 53K | -- | James Dal Porto, 48 COO,
Exec. VP, Director | 423K | $17K | Henry Tai, Ph.D., M.D., 57 Sec. | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|